Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

pt responsibility for the adequacy or accuracy of the content of this News Release. Reported financial information may not necessarily be indicative of future operating results or of future financial position, due to a number of risks and uncertainties, including those set forth below. This News Release contains certain forward-looking statements and information regarding the Company's activities and finances, which statements and information can be identified by the use of forward-looking terminology such as "future", "anticipated", "planned", "expects", "continue", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward-looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation, the risk that the $16.9 million private placement may not close, either wholly or in part, which would result in the Company continuing to need financing in the near term, which may not be available in a timely manner or at all and which, if not obtained, will have a material adverse impact on the Company and its ability to continue; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of o
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Cmed Technology , an eClinical ... and give a presentation about electronic data capture (EDC) ... Ops Executives ( SCOPE ) conference at Florida,s Westin ... As part of SCOPE,s two-day "Electronic Data In ...
... Ky., Feb. 4, 2011 MediVet-America, the leading ... animals suffering from osteoarthritis, hip dysplasia, ligament and ... year of business having achieved record advances in ... Adipose-Derived Stem Cell Procedure Kit and equipment, veterinary ...
... (Pink Sheets: AVXT ) ("AVAX" or the ... with the Securities and Exchange Commission ("SEC").  Upon the ... become a publicly reporting company.  The Company intends to ... Over-the-Counter Bulletin Board.  The Company,s Form 10, which contains ...
Cached Biology Technology:Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year 2AVAX Technologies, Inc. Files Form 10 With SEC 2
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
(Date:7/9/2014)... research has uncovered how a complex protein pivotal in ... is activated. The discovery answers a key question about ... which has been the subject of tens of thousands ... funding. , Jiazhen Zhang, a research student in Professor ... uncovered how the protein complex, called NF-κB, is activated. ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
Breaking Biology News(10 mins):Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3Research reveals how key controller protein is switched on 2UC Riverside plant pathologist receives national recognition 2
... in a jetliner act and feel one way when crammed ... a different mindset when the middle seat is empty and ... parallel that exists among the proteins involved in health and ... issue of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
... Georges Belfort has been recognized for his fundamental ... engineering. Belfort, the Russell Sage Professor of ... weeks received the 2011 Alan S. Michaels Award ... American Chemical Society (ACS) Biotechnology Division. ...
... A fascinating study published in the BMJ shows ... each week, as they drink daily, rather than more on ... disease than the Northern Irish. Ruidavets and colleagues compared groups ... have very different drinking cultures and rates of heart disease.The ...
Cached Biology News:Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2Pattern of drinking affects the relation of alcohol intake to coronary heart disease 2
...
Alexa Fluor 647 anti-mouse Qa-2...
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
... The Luminex 100 Instrument System ... multi-analyte assays using Upstate's Beadlyte reagents. ... the Dell computer with software version ... Sheath Delivery System. Upstate offers $2000 ...
Biology Products: